Skip to main content

Table 1 Clinical Characteristics and Responses of Super-Responders Treated with Anastrozole and Everolimus

From: Multiple gene aberrations and breast cancer: lessons from super-responders

Patient No.

1

2

3

Age at Treatment (years)

38

48

44

Date of Diagnosis

August 2009

September 2007

September 2010

Date of Biopsy

August 2009

September 2007

August 2010

Histology

Ductal

Ductal

Ductal

ER Status

90 % Positive

95 % Positive

95 % Positive

PR Status

60 % Positive

80 % Positive

Negative

HER2/neu Status

Negative (FISH)

Negative (FISH)

Negative (IHC)

Prior Treatment in Metastatic Setting

Paclitaxel (3 months) 5-fluorouracil, doxorubicin, cyclophosphamide (1 month) Tamoxifen (3 months) Capacitabine ( 3 months)

Tamoxifen (2 months) Paclitaxel, bevacizumaba Vinorelbinea Fulvestrant (3 months) Ixabepilonea Docetaxel (9 months) Docetaxel, doxorubicin, cyclophosphamide (3 months)

Tamoxifen, zoledronic acid (6 months) Letrozole (4 months)

Prior Treatment with Aromatase Inhibitor in Metastatic Setting (Duration)

No

No

Yes (4 months)

Molecular alterations (Please reference Additional file 1: Table S1)

   

Progression Free Survival (months)

11

14

9+

Best Response (%)

−56 %

−38 %

−100 %

  1. aUnknown duration of treatment
  2. FISH Fluorescent in-situ hybridization, IHC Immunohistochemistry